AIP Checklist 1 Supplementary Information Titles Journal: Nature Medicine Article Title: Modelling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids Corresponding Author: Toshiro Sato Supplementary Item & Number Title or Caption Supplementary Figure 1 Establishment of CRISPR-Cas9-engineered organoids. Supplementary Figure 2 CRISPR-Cas9-mediated introduction of mutations in driver pathways. Supplementary Figure 3 Heat maps of differentially expressed genes in engineered organoids. Supplementary Figure 4 Establishment of lentivirally engineered organoids. Supplementary Figure 5 Tumour grafts of lentivirally engineered organoids Supplementary Figure 6 Tumour grafts of CRISPR-Cas9-engineered organoids and CRC organoids. Supplementary Figure 7 Global gene expression of adenoma, engineered and CRC organoids. Supplementary Figure 8 Sequence analysis of engineered organoids. Supplementary Figure 9 Establishment of engineered adenoma organoids. Supplementary Table 1 Summary of clinical information Supplementary Table 2 Gene targeting efficiency of CRISPR-Cas9 in human colonic organoids. Supplementary Table 3 Sequence analysis of predicted off-target loci of CRISPR/Cas- 9 edited organoids. Supplementary Table 4 Oligonucleotides used in this study. Nature Medicine: doi:10.1038/nm.3802
13
Embed
Supplementary Information Titles · efficiency of gene introduction. The antibiotics - or niche factor- selected organoids were verified by Sanger sequencing analysis. Recipient Cells
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
AIP Checklist 1
Supplementary Information Titles
Journal: Nature Medicine
Article Title: Modelling colorectal cancer using CRISPR-Cas9-mediated
engineering of human intestinal organoids
Corresponding
Author:
Toshiro Sato
Supplementary Item & Number
Title or Caption
Supplementary Figure 1 Establishment of CRISPR-Cas9-engineered organoids.
Supplementary Figure 2 CRISPR-Cas9-mediated introduction of mutations in driver
pathways.
Supplementary Figure 3 Heat maps of differentially expressed genes in engineered
organoids.
Supplementary Figure 4 Establishment of lentivirally engineered organoids.
Supplementary Figure 5 Tumour grafts of lentivirally engineered organoids
Supplementary Figure 6 Tumour grafts of CRISPR-Cas9-engineered organoids and
CRC organoids.
Supplementary Figure 7 Global gene expression of adenoma, engineered and CRC
organoids.
Supplementary Figure 8 Sequence analysis of engineered organoids.
Supplementary Figure 9 Establishment of engineered adenoma organoids.
Supplementary Table 1 Summary of clinical information
Supplementary Table 2 Gene targeting efficiency of CRISPR-Cas9 in human colonic
organoids.
Supplementary Table 3 Sequence analysis of predicted off-target loci of CRISPR/Cas-
9 edited organoids.
Supplementary Table 4 Oligonucleotides used in this study.
Nature Medicine: doi:10.1038/nm.3802
Supplementary Figure 1
Supplementary Figure 1: Establishment of CRISPR-Cas9-Engineered Organoids. (a) Summary of strategy for
CRISPR-Cas9-based organoid engineering. (b) Summary of clinical information for organoids used in this study. R:
Rectum, FAP: familial adenomatous polyposis. (c) Generation of second and third line of CRISPR-Cas9-engineered
organoids. Sequences of del (deletions) and ins (insertions) are shown in Supplementary Fig. 8b,c.